NCT01156792 - Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Asthma

Interventions

DRUG

FP 100

FP 100mcg BID

DRUG

GSK2190915 100

GSK2190915 100mg QD (AM)

DRUG

GSK2190915 300

GSK2190915 300mg QD (AM)

DRUG

montelukast

montelukast 10mg QD (PM)

DRUG

placebo

placebo BID

DRUG

FP/SAL 100/50

FP/SAL 100/50mcg BID

Trial Locations (32)

15241

GSK Investigational Site, Pittsburgh

18020

GSK Investigational Site, Bethlehem

28401

GSK Investigational Site, Wilmington

29118

GSK Investigational Site, Orangeburg

33134

GSK Investigational Site, Coral Gables

33173

GSK Investigational Site, Miami

35209

GSK Investigational Site, Birmingham

42301

GSK Investigational Site, Owensboro

44718

GSK Investigational Site, Canton

45231

GSK Investigational Site, Cincinnati

46208

GSK Investigational Site, Indianapolis

48197

GSK Investigational Site, Ypsilanti

53792

GSK Investigational Site, Madison

55402

GSK Investigational Site, Minneapolis

63110

GSK Investigational Site, St Louis

63141

GSK Investigational Site, St Louis

66215

GSK Investigational Site, Lenexa

70006

GSK Investigational Site, Metairie

72205

GSK Investigational Site, Little Rock

73103

GSK Investigational Site, Oklahoma City

75024

GSK Investigational Site, Plano

75230

GSK Investigational Site, Dallas

76712

GSK Investigational Site, Waco

77054

GSK Investigational Site, Houston

78750

GSK Investigational Site, Austin

90048

GSK Investigational Site, Los Angeles

92083

GSK Investigational Site, Vista

92647

GSK Investigational Site, Huntington Beach

04401

GSK Investigational Site, Bangor

68123-4303

GSK Investigational Site, Bellevue

07712

GSK Investigational Site, Ocean City

05403

GSK Investigational Site, South Burlington